BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 30, 2013
View Archived Issues
Epizyme to develop companion diagnostics for two novel HMT inhibitors
Read More
New software application for personalized medicine presented
Read More
Listeria-based prostate cancer vaccines developed at Aduro BioTech
Read More
Glytech designs novel cancer immunotherapeutic
Read More
Maruishi Pharmaceutical and Cara Therapeutics sign license agreement for CR-845
Read More
UCB updates pipeline progress of first quarter 2013
Read More
Humanized anti-cocaine MAb demonstrates in vivo efficacy
Read More
Angion Biomedica presents CYP17 inhibitors for the treatment of prostate cancer
Read More
AstraZeneca reports activities of first quarter 2013
Read More
MorphoSys begins phase II MOR-208 trial
Read More
Phase II results presented for solithromycin in the treatment of urogenital gonorrhea
Read More
Novel selective PI3K-beta isoform inhibitors show promising oncolytic properties
Read More
Merck & Co. discloses new JAK inhibitors
Read More
GlaxoSmithKline prepares novel fatty acid synthase inhibitors
Read More
Novartis synthesizes new histamine H3 receptor antagonists/agonists
Read More
Alimera Sciences launches Iluvien in the U.K.
Read More
Merck & Co. and Pfizer to develop and commercialize ertugliflozin
Read More
Gilead receives FDA complete response letters for elvitegravir and cobicistat
Read More
Nuvilex to advance Cell-in-a-Box technology to phase III
Read More
Addex's GABA(B) receptor PAM reduces alcohol intake in preclinical model
Read More
FDA accepts for review Octapharma's BLA for investigational 4-factor PCC octaplex
Read More
Theravance board of directors approves plan to split into two publicly traded companies
Read More
Impax Pharmaceuticals and GSK terminate IPX-066 collaboration
Read More
Veloxis Pharmaceuticals submits MAA to EMA for LCP-Tacro
Read More
Novartis initiates phase II trial of INC-280 triggering milestone payment to Incyte
Read More
SD-101 receives FDA breakthrough therapy designation for epidermolysis bullosa
Read More